相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials
Linda T. Vahdat et al.
SUPPORTIVE CARE IN CANCER (2012)
Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients
Rebecca M. Speck et al.
SUPPORTIVE CARE IN CANCER (2012)
Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions
Murray J. Towle et al.
CANCER RESEARCH (2011)
Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
Krystyna M. Wozniak et al.
CANCER RESEARCH (2011)
Chemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment
D. R. Pachman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
Jennifer A. Smith et al.
BIOCHEMISTRY (2010)
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Linda T. Vahdat et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Tatiana Okouneva et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer
Eva Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
E. A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
MA Jordan et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389
G Kuznetsov et al.
CANCER RESEARCH (2004)
分享论文
